top of page


Fast and spurious
Did you ever wonder: Hey, the original SARS outbreak was 15 years ago, why don’t we just use the SARS vaccine we put our (and every...


Target practice
The early days of the COVID-19 pandemic have seen a rush to repurpose existing approved or near approval drugs, due to the urgency of the...


Skip it
Imagine you had a drug that dramatically improved the symptoms or signs of a disease in 70% of the patients who take it, but carried the...


A tissue a tasket
It seems like an obvious concept: Let's say you are developing a drug that works by inhibiting, say, phosphodiesterase-4 (PDE-4) to treat...

Cis boom–bah!
After the euphoria of the discovery of the viral cause of AIDS (1984) came the growing (e.g. Dallas Buyer’s Club) desperation as that...

Meh-dicine
The holy grail of the pharma industry is FDA approval, but the final clue may be positive top-line (Phase III) results. However, it is...


Stop culture
We waited a long time for a real gene therapy, though we were promised it would be easy. So now we are feeling optimistic about the other...

Stumbling block
In any competitive sport, you know that what worked one time down the field/floor/ice is VERY unlikely to work again the second time. We...

Shock drop
There are drug adverse events, and then there are the Voldemorts of drug adverse effects, whose which-must-not-be-named. Bleeding in...

Clot twist
Just when you thought you were out, they pull you back in. We in the business obsess over the “valley of death” and the drug development...
Blog: Blog
bottom of page